The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
 
Jin-Ji Yang
No Relationships to Disclose
 
Nick Pavlakis
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck KGaA; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - Bayer (Inst); Pfizer (Inst); Roche (Inst)
 
Fan Xie
Employment - Genor BioPharma
Stock and Other Ownership Interests - Genor BioPharma
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)